论文部分内容阅读
[目的]分析用高效抗逆转录病毒疗法(HAART)治疗艾滋病(AIDS)的效果,探讨相关影响因素。[方法]采用HAART治疗99例,观察治疗组和非治疗组的死亡差异和治疗前后CD4+T淋巴细胞水平变化。[结果]1991—2005年,2007、2008和2009年确诊为AIDS的治疗组病死率低于非治疗组;治疗后病人外周静脉血CD4+T淋巴细胞计数平均增加(189±191)个/μl;治疗死亡组开始治疗时基线CD4+T淋巴细胞平均水平明显低于治疗存活组。[结论]HAART可增加患者CD4+T淋巴细胞,帮助免疫重建,降低病死率。应加大AIDS筛查力度,及早发现病人,加强随访和监测,适时启动治疗。
[Objective] To analyze the effect of treating AIDS with highly effective antiretroviral therapy (HAART) and explore the related factors. [Methods] Ninety-nine patients were treated with HAART. The difference of death and the levels of CD4 + T lymphocytes before and after treatment were observed in treatment group and non-treatment group. [Results] The case fatality rate of AIDS-treated patients in 1991-2005, 2007, 2008 and 2009 was lower than that of non-treatment patients. After treatment, the average peripheral blood CD4 + T lymphocyte count increased (189 ± 191) / μl ; The average level of baseline CD4 + T lymphocytes in the treatment-death group at the start of treatment was significantly lower than that of the treatment-survived group. [Conclusion] HAART can increase CD4 + T lymphocytes in patients, help immune reconstruction and reduce mortality. AIDS screening should be strengthened, early detection of patients, strengthen follow-up and monitoring, timely start treatment.